Deutsche Bank AG Acquires 75,994 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Deutsche Bank AG boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 217,723 shares of the company's stock after purchasing an additional 75,994 shares during the quarter. Deutsche Bank AG owned 0.06% of Recursion Pharmaceuticals worth $1,472,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RXRX. Accel Wealth Management acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $310,000. Rockefeller Capital Management L.P. increased its stake in Recursion Pharmaceuticals by 323.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after acquiring an additional 215,283 shares during the period. Institute for Wealth Management LLC. acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at approximately $3,928,000. Invesco Ltd. lifted its position in shares of Recursion Pharmaceuticals by 54.6% in the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company's stock worth $1,207,000 after acquiring an additional 63,068 shares during the period. Finally, Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $23,429,000. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of recent research reports. Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Morgan Stanley reduced their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX traded up $0.06 on Thursday, hitting $4.45. The stock had a trading volume of 21,617,503 shares, compared to its average volume of 13,611,536. The firm's 50 day moving average price is $4.95 and its 200-day moving average price is $6.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -2.91 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.39) earnings per share. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.